Intralipid is a synthetic mixture which consists of 10% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water. It is administered through an IV drip on the arm. The purpose of intralipid infusion is to lower the activity of natural killer cells, and therefore, reduce the likelihood of an implantation failure caused by the presence of natural killer cells. More commonly, this drug is given to patients who exhibit symptoms of essential fatty-acid deficiency.
What Does Intralipid Infusion Typically Provide?
Intralipid infusion (also referred to as lipid emulsion) provides essential fatty acids or EFAs that are necessary for people with particular disorders. A few of the disorders are:
– Irritable Bowel Syndrome (IBS)
– Attention Deficit Disorder (ADD)
– Arthritis (source)
The EFAs that intralipid infusion provides are Omega-3 and Omega-6 fatty-acids (linoleic and alpha-linolenic acids respectively). Omega-3 fatty acids are necessary for brain development from pregnancy onward until the child is two-years-old. Infusion of intralipid infusion is well-targeted at suppressing natural killer cell activity or NKa.
In certain people, the white blood cells have a hard time determining the difference between an embryo and an intruder. This causes the body to reject the implanted egg and flush it from the system.
Who needs Intralipid Infusion?
Couples with repeated IVF failures or recurrent miscarriages will be referred to a lab to test for presence of natural killer cells. This will be done via a blood test and depending on your test result, your suitability for intralipid infusion therapy will be assessed. If you have tested positive for high level of natural killer cells, then we will make the necessary arrangements so that your intralipid infusion can be scheduled during your treatment.
Intralipid Research and IVF:
Natural killer cells are a type of white blood cells that help contain viral infections. Presence of a high number of natural killer cells can signal to your body to treat an implanting embryo as an invading cell or a foreign object and therefore attack it. This suggests that you may have an overactive immune system which may need to be suppressed. Recently, intralipid infusion shows to be extremely effective in the subduing of NK (natural killer) cells or white blood cells.
Intralipid in recurrent Pregnancy Loss:
Women with recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) tend to have elevated levels of a subset of white blood cells known as natural killer cells (NK cells). This intralipid mixture acts to “down regulate” these natural killer cells that are thought to attack a developing embryo and prevent its implantation. Intralipids are believed to interfere with the signals in the immune system to stop the attack or rejection of the embryo
Intralipid is effective in enhancing live birth rates among women with elevated NK cell cytotoxicity and a history of recurrent implantation failure and recurrent pregnancy loss.
Intralipid Dosage Frequency
Intralipid is normally administered both prior and during the attempt at conceiving a child. The drug is often given once or twice prior to the pregnancy and is prolonged by one dosage per month after the initial conception attempt. Throughout the period prior-to and during conception, tests are performed by a physician that will determine or alter the administration of intralipid.
Intralipid is given via an intravenous infusion control pump. The limits are usually 2.5 grams per kilogram of the person’s weight, meaning that an average female would intake 177 grams of 20 percent of an intralipid admixture compound.
Possible side effects of intralipid infusions.
Headache, dizziness, flushing, drowsiness, nausea, vomiting or sweating may occur.
While research is still continuing on the topic of intralipid infusions and the positive effects it can have on IVF treatments, women who have endured repeated failed IVF treatments are given a bit of fresh hope with the new combination of IVF and intralipid infusion and the possibility for increasing IVF success rates.